|
PWZ-029 is a benzodiazepine derivative drug with nootropic effects developed by WiSys,〔US Patent application US2006/258643 A1〕 It acts as a subtype-selective, mixed agonist-inverse agonist at the benzodiazepine binding site on the GABAA receptor, acting as a partial inverse agonist at the α5 subtype and a weak partial agonist at the α3 subtype. This gives it a mixed pharmacological profile, producing at low doses memory-enhancing effects but with no convulsant or anxiogenic effects or muscle weakness, although at higher doses it produces some sedative effects.〔Savić MM, Clayton T, Furtmüller R, Gavrilović I, Samardzić J, Savić S, Huck S, Sieghart W, Cook JM. PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats. ''Brain Research''. 2008 May 7;1208:150-9. PMID 18394590〕 ==See also== * α5IA * Basmisanil * L-655,708 * Ro4938581 * TB-21007 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「PWZ-029」の詳細全文を読む スポンサード リンク
|